RVMD - Revolution Medicines Inc logo

Revolution Medicines Inc

RVMD

Revolution Medicines develops targeted therapies for RAS-addicted cancers, focusing on RAS(ON) inhibitors and companion inhibitors. Its pipeline includes investigational drugs for solid tumors, particularly pancreatic ductal adenocarcinoma and non-small cell lung cancer.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago →$6,875today

Score Overview

1 Year
Score—
Net Growth-56.31%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score0.5
Net Growth-7x
Net TrendNever
Net Income Consistency—
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency—
All Time
Score
Net Growth-14x
Net TrendNever
Net Income Consistency
Rev Growth-100.00%
Rev Trend17%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Revolution Medicines Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. RVMD does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 187.69—
1 Year2025-10-22
$ 52.98254.27%
5 Years2021-10-22
$ 27.306x
All Time2020-02-13
$ 28.906x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 1.76B$ 3.93B
2025$ 0.00-$ 1.13B$ 2.02B
2024$ 0.00-$ 600M$ 2.28B
2023$ 11M-$ 436M$ 1.85B
2022$ 35M-$ 248M$ 644M
2021$ 29M-$ 187M$ 577M
IPO2020$ 42M-$ 108M$ 440M
RVMD - Revolution Medicines Inc logo

Revolution Medicines Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 42M to $ 0.00 and net income went from -$ 108M to -$ 1.13B. Revenue increased in 1 of those 5 years; net income in 0.

Revolution Medicines Inc currently holds a 5-year HDB Score of 0.5 out of 10. How the HDB Score is calculated.

Membership

Explore RVMD with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies